Physician profile
Treg Brown
NPI 1598870115
$6,550,704.47
in general payments reported to CMS, 2019-2025
22 companies · $1.5M in 2025
The $1.5M reported for 2025 was more than what 99% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $696K · 2020: $708K · 2021: $871K · 2022: $868K · 2023: $956K · 2024: $968K · 2025: $1.5M.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $3.4M · Food and Beverage: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $3,408,283.49 |
| Food and Beverage | $159.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $6,547,017.58 | 2019-2025 | Q-Fix |
| Medical Device Business Services, INC. | $2,340.00 | 2019 | |
| Kci USA, INC. | $452.36 | 2019-2021 | |
| Depuy Synthes Sales INC. | $233.03 | 2019-2021 | |
| Pacira Pharmaceuticals Incorporated | $110.32 | 2019 | |
| Ferring Pharmaceuticals INC. | $95.16 | 2019-2025 | Euflexxa |
| Stryker Corporation | $56.47 | 2022-2024 | Mako |
| Pacira Therapeutics, INC. | $53.40 | 2020-2021 | |
| Vertex Pharmaceuticals Incorporated | $53.25 | 2025 | |
| Elite Orthopedics, LLC | $40.81 | 2021-2022 | |
| Fidia Pharma USA INC. | $33.10 | 2019 | |
| Amgen INC. | $30.73 | 2020-2024 | Krystexxa |
| Pfizer INC. | $28.32 | 2019 | |
| Endo Pharmaceuticals INC. | $27.83 | 2019 | |
| Si-Bone, INC. | $25.27 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heraeus Medical, LLC. | $20.04 | 2023 | Palacos |
| Ermi LLC | $19.31 | 2022 | |
| Allergan, INC. | $16.45 | 2020 | |
| Abbvie INC. | $13.88 | 2022 | |
| Vericel Corporation | $13.15 | 2019 | |
| Bioventus LLC | $12.18 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Treg Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.